Coho Partners LTD Has Decreased Aflac (AFL) Stake; Profile of 3 Analysts Covering AMAG Pharmaceuticals, Inc. (AMAG)

January 18, 2018 - By Winifred Garcia

Among 13 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 3 have Buy rating, 1 Sell and 9 Hold. Therefore 23% are positive. AMAG Pharmaceuticals had 34 analyst reports since August 18, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, June 6 by Jefferies. The firm has “Underperform” rating given on Monday, January 9 by Raymond James. The stock has “Buy” rating by Jefferies on Thursday, August 11. Morgan Stanley initiated the stock with “Buy” rating in Friday, September 8 report. The firm earned “Mkt Perform” rating on Tuesday, January 10 by Leerink Swann. Cantor Fitzgerald maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Monday, June 26 with “Hold” rating. Jefferies maintained the shares of AMAG in report on Wednesday, August 16 with “Buy” rating. The stock has “Outperform” rating by Raymond James on Tuesday, September 1. The firm earned “Hold” rating on Monday, July 24 by Cantor Fitzgerald. The company was downgraded on Wednesday, January 11 by Needham. See AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) latest ratings:

07/12/2017 Broker: FBR Capital Rating: Hold New Target: $16.0
03/11/2017 Broker: Jefferies Rating: Buy New Target: $16.0 Maintain
03/11/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $26 New Target: $22 Maintain
02/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0 Maintain
23/10/2017 Broker: PiperJaffray Rating: Neutral New Target: $18 Initiates Coverage On
17/10/2017 Broker: Janney Capital Rating: Hold
08/09/2017 Broker: Morgan Stanley Rating: Buy New Target: $26.0 Initiate
16/08/2017 Broker: Jefferies Rating: Buy New Target: $34.0 Maintain
24/07/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $23.0000 Maintain

Coho Partners Ltd decreased Aflac Inc. (AFL) stake by 6.7% reported in 2017Q3 SEC filing. Coho Partners Ltd sold 146,537 shares as Aflac Inc. (AFL)’s stock rose 3.90%. The Coho Partners Ltd holds 2.04 million shares with $166.07M value, down from 2.19 million last quarter. Aflac Inc. now has $34.15 billion valuation. The stock decreased 1.09% or $0.96 during the last trading session, reaching $86.86. About 1.68 million shares traded. Aflac Incorporated (NYSE:AFL) has risen 7.68% since January 18, 2017 and is uptrending. It has underperformed by 9.02% the S&P500.

Since August 4, 2017, it had 0 insider buys, and 6 sales for $2.69 million activity. On Thursday, September 21 HUDSON ELIZABETH J sold $107,132 worth of Aflac Incorporated (NYSE:AFL) or 1,279 shares. $25,907 worth of stock was sold by TILLMAN AUDREY B on Thursday, October 26. On Friday, September 29 Daniels James Todd sold $50,525 worth of Aflac Incorporated (NYSE:AFL) or 620 shares. Another trade for 25,000 shares valued at $2.10 million was made by CLONINGER KRISS III on Thursday, September 21. 1,500 shares were sold by JOHNSON DOUGLAS WAYNE, worth $125,363.

Analysts await Aflac Incorporated (NYSE:AFL) to report earnings on January, 30. They expect $1.55 earnings per share, up 0.65% or $0.01 from last year’s $1.54 per share. AFL’s profit will be $609.38M for 14.01 P/E if the $1.55 EPS becomes a reality. After $1.70 actual earnings per share reported by Aflac Incorporated for the previous quarter, Wall Street now forecasts -8.82% negative EPS growth.

Investors sentiment decreased to 0.89 in 2017 Q3. Its down 0.08, from 0.97 in 2017Q2. It worsened, as 44 investors sold AFL shares while 297 reduced holdings. 73 funds opened positions while 232 raised stakes. 250.65 million shares or 1.32% less from 254.01 million shares in 2017Q2 were reported. Whitnell & has 1.46% invested in Aflac Incorporated (NYSE:AFL) for 41,185 shares. Fiduciary Trust owns 25,422 shares for 0.06% of their portfolio. Raymond James Na has 0.14% invested in Aflac Incorporated (NYSE:AFL) for 23,761 shares. Cantab Prtn Llp owns 28,356 shares for 0.33% of their portfolio. Farmers And Merchants Invests holds 0.52% or 81,113 shares. Principal holds 0.07% or 905,980 shares in its portfolio. North Star Investment Mgmt Corporation holds 300 shares. Cap Inv Advsrs Lc owns 57,645 shares or 0.32% of their US portfolio. Stratos Wealth accumulated 0.04% or 11,144 shares. Germany-based Dekabank Deutsche Girozentrale has invested 0.23% in Aflac Incorporated (NYSE:AFL). Brown Advisory Inc has invested 0.03% in Aflac Incorporated (NYSE:AFL). Wright Investors Service reported 0.32% in Aflac Incorporated (NYSE:AFL). 1832 Asset Mgmt LP stated it has 7,800 shares or 0% of all its holdings. 68,604 are owned by Cornercap Counsel Incorporated. Renaissance Group Limited Co invested in 2,549 shares.

Among 18 analysts covering Aflac Incorporated (NYSE:AFL), 2 have Buy rating, 4 Sell and 12 Hold. Therefore 11% are positive. Aflac Incorporated had 48 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Underperform” rating given on Friday, December 9 by RBC Capital Markets. The firm has “Sell” rating by RBC Capital Markets given on Tuesday, September 5. The stock has “Sell” rating by RBC Capital Markets on Monday, October 9. The firm earned “Hold” rating on Tuesday, January 9 by Wells Fargo. Deutsche Bank maintained Aflac Incorporated (NYSE:AFL) on Monday, December 5 with “Hold” rating. The firm has “Sell” rating by RBC Capital Markets given on Monday, July 31. The firm has “Neutral” rating given on Thursday, January 26 by Citigroup. The firm has “Sector Perform” rating given on Tuesday, February 2 by RBC Capital Markets. The firm earned “Market Perform” rating on Friday, September 23 by Wells Fargo. Barclays Capital maintained it with “Equal-Weight” rating and $79 target in Friday, August 11 report.

Investors sentiment increased to 1.44 in Q3 2017. Its up 0.35, from 1.09 in 2017Q2. It is positive, as 21 investors sold AMAG Pharmaceuticals, Inc. shares while 43 reduced holdings. 35 funds opened positions while 57 raised stakes. 39.98 million shares or 4.47% less from 41.85 million shares in 2017Q2 were reported. Goldman Sachs Group Inc has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). First Midwest Bancorporation Trust Division has 43,844 shares for 0.1% of their portfolio. Citigroup reported 0% stake. Matarin Cap Mgmt Ltd Liability reported 0.06% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Canada Pension Plan Invest Board holds 7,800 shares or 0% of its portfolio. Morgan Stanley stated it has 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). California State Teachers Retirement System invested in 0% or 56,498 shares. Grp Incorporated One Trading Limited Partnership reported 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Stevens Cap Mngmt L P reported 26,084 shares. Dekabank Deutsche Girozentrale accumulated 18,650 shares. State Street has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Vanguard Grp Inc Inc has invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Qs Invsts Limited Liability Company holds 109,898 shares. Systematic Mngmt L P reported 84,590 shares stake. Aqr Capital Mgmt Limited Liability Company invested in 233,319 shares or 0.01% of the stock.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $469.59 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>